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Viruses, during the course of their replication, alter several important intracellular 
processes. These changes may trigger various regulated cell death subroutines, such as 
apoptosis, anoikis, necroptosis, parthanatos, pyroptosis and autophagy. Cell destruction 
plays an important role in the pathogenesis of viral infections, and also affects the 
development of the clinical symptoms. 
I. Major cell death subroutines 
Apoptosis is a major form of cell death characterized by specific morphological signs, 
such as cell shrinkage, membrane blebbing and chromatin condensation. Two main 
evolutionarily conserved protein families are involved in apoptosis, namely the Bcl-2 
family member proteins, which control mitochondrial integrity (1, 2) and the cysteinyl 
aspartate-specific proteases or caspases, which mediate the execution phase of 
apoptosis. (3) Apoptosis is classified into two cell death subroutines: (i) the extrinsic 
and (ii) the intrinsic apoptosis. (4-7) Extrinsic apoptosis is a caspase-dependent cell 
death pathway that is induced by binding of lethal ligands to death receptors, such as 
Fas/CD95, tumor necrosis factor (TNF) α receptor 1 and TNF-related apoptosis 
inducing ligand receptor. (8, 9) Ligand binding triggers the assembly of a 
supramolecular complex termed death inducing signaling complex (DISC) at the 
cytoplasmic tail of the receptor. (10, 11) DISC functions as a platform that regulates the 
activation of caspase-8 or -10. (11-13) Intrinsic apoptosis is triggered by various 
intracellular stress conditions, including DNA damage, oxidative stress, cytosolic Ca2+ 
overload, and accumulation of unfolded proteins in the cytoplasm. (4) Signaling 
cascades that trigger intrinsic apoptosis converge in mitochondria and elicit 
mitochondrial outer membrane permeabilization (MOMP). MOMP leads to bioenergetic 
and metabolic catastrophe via several mechanisms, including disruption of the 
mitochondrial transmembrane potential, inhibition of the respiratory chain, and release 
of toxic proteins from the mitochondrial intermembrane space into the cytosol. (14-17)   
Anoikis is an ancient Greek term meaning the ‘state of being homeless’. (18, 19) 
Anoikis is a particular apoptotic cell death that occurs in adherent cells in response to 
forced detachment from the matrix. (20, 21) This form of cell demise can become 
activated by the lack of β1-integrin, downregulation of epidermal growth factor receptor 
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expression, inhibition of extracellular-regulated kinase 1 signaling, and overexpression 
of the Bcl-2-interacting mediator of cell death (Bim) protein. (18, 21) The cell death 
program of anoikis is driven by the molecular machinery of intrinsic apoptosis. (21, 22) 
Death of normal cells by way of anoikis inhibits dysplastic growth by preventing 
reattachment of displaced cells to new matrices. (20) Resistance to anoikis of 
transformed epithelial cells facilitates invasiveness and increases metastatic potential. 
(23-25) 
Necrosis is an accidental form of cell death that can be caused by external factors, 
such as infection, toxins, cancer, infarction, poisons, ROS (Reactive Oxygen Species), 
inflammation or trauma. (26) Necrotic cell death is characterized by cytoplasmic and 
organelle swelling, followed by the loss of cell membrane integrity and release of the 
cellular contents into the surrounding extracellular space.  
Necrosis can also occur in a regulated manner. (27, 28) Regulated necrosis or 
necroptosis can be triggered by members of the TNF family, Toll-like receptors (TLR3 
and TLR4) and DNA and/or RNA sensors. (27) Necroptosis is characterized by the lack 
of specific apoptotic markers, such as caspase activation, while it depends on the 
activation of receptor-interacting protein 1 (RipK1) and RipK3 kinases. (29, 30) 
Necroptosis leads to rapid plasma membrane permeabilization, release of cell contents, 
and exposure of damage-associated molecular patterns (DAMPs). It has an important 
role in T cell homeostasis, and during viral infections necroptosis works as a back-up 
mechanism to eliminate the pathogen. (28)  
Parthanatos is a particular case of regulated necrosis. Parthanatic cell demise 
characteristically depends on early activation of poly(ADP-ribose) polymerase 1 
(PARP1). (31) PARP1 overactivation triggers depletion of NAD+ and ATP, disruption 
of the mitochondrial transmembrane potential, and release of apoptosis-inducing factor, 
which in turn leads to chromatinolysis. (32, 33) 
Pyroptosis is a more recently recognized form of regulated cell death with biochemical 
properties distinct from necrosis and apoptosis. (26, 34, 35) This cell death subroutine 
has initially been described in some infections caused by bacteria, such as Salmonella 
Typhimurium, Shigella flexneri, Francisella tularensis, Listeria monocytogenes and 
Pseudomonas aeruginosa. (35-39) Later, several other pyroptosis inducers have also 
been identified. (40, 41) The central mediator in the molecular mechanism of pyroptosis 
is caspase-1, which is activated in the cytosol by the inflammasome or pyroptosome. 
(35, 42) The inflammasome is a multiprotein complex composed of Nod-like receptors, 
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the adaptor protein Asc (apoptosis-associated speck-like protein containing a caspase 
activation and recruitment domain) and caspase-1. The pyroptosome is a 
supramolecular complex of Asc dimers. (42, 43) Activated caspase-1 induces the 
formation of ion-permeable pores with a diameter of 1.1 - 2.4 nm in the plasma 
membrane, and causes cell swelling and lysis. (44) In addition, caspase-1 activation 
causes the cleavage of some inflammatory cytokines such as pro-interleukin-1β (IL-1 β) 
and pro-IL-18 and thereby initiates an inflammatory response. (45)  
Autophagy is an essential catabolic process that maintains cellular integrity by 
degrading cytoplasmic constituents and organelles. (46-48) It is highly activated by 
several pathological conditions, including nutrient starvation, oxidative stress, 
inflammation and infections. (49, 50) Autophagy can deliver sequestered cytoplasmic 
content, damaged proteins, organelles or pathogens to the lysosomal compartment using 
a double-membraned autophagosomal vacuole as a carrying vehicle. (47, 51-53) Under 
conditions of mild stress, autophagy plays a cytoprotective role by eliminating 
pathogenic microorganisms and dysfunctional organelles. In contrast, under conditions 
leading to massive cell damage, excessive autophagy possesses destructive power 
culminating in cell demise. (54-56) Autophagic cell demise is a cell death subroutine 
that can be blocked by pharmacological or genetic inhibition of the autophagic process. 
(57) 
 
Autophagy and its role in cell homeostasis  
In eukaryotic cells, three types of autophagy have been described: (i) microautophagy, 
(ii) chaperone-mediated autophagy, and (iii) macroautophagy.  
In microautophagy, portions of the cytoplasm are engulfed by the lysosome directly. 
(46, 58, 59)  
In chaperone-mediated autophagy, unfolded proteins are translocated directly across 
the limiting membrane of the lysosome. (60, 61) 
In macroautophagy (hereafter referred to as autophagy), portions of the cytoplasm and 
organelles are sequestered into double-membrane vesicles termed autophagosomes, and 
delivered to lysosomes by vesicular transport. (47, 51-53) Macroautophagy is induced 
by nutrient deprivation, cellular stress, infections or rapamycin treatment via complex 
signaling pathways. (53, 62, 63) The major regulator of macroautophagy is the mTOR 
(mammalian target of rapamycin) protein. (64, 65) The mTOR senses the nutrient 
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supply, energy status and growth factors, and inhibits the induction of autophagy. (64) 
Environmental stressors, starvation or rapamycin treatment inhibit the mTOR, and 
thereby trigger an increase in autophagic activity. (64, 65) Following the induction of 
autophagy, inhibition of the mTOR leads to the activation of the ULK1 [autophagy-
related gene 1 (Atg1) homolog] complex, which in turn undergoes translocation to a 
certain domain of the endoplasmic reticulum (ER). Once in the ER, the ULK1 complex 
activates the class III phosphatidylinositol 3-kinase (PI3K) complex. The activated 
PI3K phosphorylates the ER lipid phosphatidylinositol at position 3 of the inositol ring. 
Phosphatidylinositol 3-phosphate then recruits double FYVE-containing protein 1 
(DFCP1) and promotes the formation of the omegasome from which the isolation 
membrane appears to be generated.  (66, 67) The isolation membrane provides a 
platform for two ubiquitin-like conjugation systems implicated in the elongation step. 
The first conjugation system, consisting of Atg7 (E1-like enzyme) and Atg10 (E2-like 
enzyme), triggers the covalent conjugation of Atg12 to Atg5. The Atg12–Atg5 
conjugate binds Atg16 and forms an E3-like enzyme. (53, 56) The second conjugation 
system, consisting of Atg7 (E1-like enzyme) and Atg3 (E2-like enzyme), triggers the 
covalent conjugation of phosphatidylethanolamine to the soluble microtubule-associated 
protein 1 light chain 3-I (LC3-I), leading to the formation of LC3-II. The Atg12–Atg5–
Atg16 supercomplex is required for the incorporation of LC3-II to the isolation 
membrane. (68, 69) Accumulation of the lipidated form of LC3 is essential for the 
expansion and closure of the autophagosome membrane. (68-70) Since LC3-II persists 
in the autophagosome membrane even after the autophagosome - lysosome fusion, it is 
an excellent marker for detecting autophagy. Maturation is the final, degradative stage 
of the process, when closed autophagosomes fuse with late lysosomal organelles, 
generating autolysosomes in which the engulfed material is then degraded. (68, 70) 
Selective autophagy is a special form of macroautophagy in which misfolded proteins 
labeled with ubiquitin or pathogenic microorganisms decorated with ‘eat me’ signals are 
captured selectively by cargo receptors, such as p62/sequestosome-1 (SQSTM1), 
neighbor of BRCA1 gene 1 protein (NBR1), nuclear domain 10 protein 52 (NDP52) 
and optineurin. (71-73) The adaptors bind to LC3 via a domain known as LIR (LC3 
interacting region), and deliver their substrates to autophagosomes. (74) 
Autophagy plays important roles in numerous physiological processes and 
pathological conditions, including infections. (46, 75, 76) Autophagic capture and 
delivery of viruses to lysosomes can severely compromise viral replication, and may 
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function as an ancient antiviral defense mechanism known as xenophagy. (77) Several 
viruses have evolved different strategies to elude the destructive power of autophagy. 
Some viruses can prevent autophagic recognition, block autophagosomal initiation and 
maturation or inhibit the fusion of lysosomes with autophagosomes, while others utilize 
autophagy to their own advantage. (78-80)  
 
II. Rubella virus and its interaction with the infected cells 
Rubella virus (RV), the sole member of the Rubivirus genus in the Togaviridae family, 
can cause postnatal and congenital infections.  Postnatal RV infection, known as rubella 
disease or German measles, is one of the five classic childhood diseases. By disturbing 
the ontogeny of fetal organs, congenital RV infection may lead to serious 
developmental abnormalities, collectively termed the congenital rubella syndrome 
(CRS). (81) 
 
Structure and replication of RV  
RV is an enveloped virus with a positive-sense, single-stranded RNA genome. (81) 
RV virions are spherical particles with a diameter of 55 - 90 nm. They have an electron-
dense nucleocapsid core surrounded by a host-derived envelope. The RV nucleocapsid 
has icosahedral symmetry. The genome of RV contains about 70% guanine and 
cytosine, the highest of all sequenced RNA viruses. (82) The genome contains two open 
reading frames (ORFs). (81, 82) The 5’ ORF encodes the two non-structural proteins 
(p150 and p90). (82-86) p150 possesses an ADP-ribose-binding domain, a sequence 
with a proline-rich region, and motifs for methyltransferase and papain-like cysteine 
protease, while p90 comprises domains for replicase and helicase. (82, 84) The 3’ ORF 
encodes the structural proteins, including the capsid (C) protein, and also the E1 and E2 
envelope glycoproteins. (82)   
The most characteristic feature of RV is that its intracellular life cycle is closely 
connected to the endomembrane system. RV enters the cells by using the endocytic 
pathway, and as early endosomes mature into late endosomes, acidification triggers the 
fusion of the RV envelope to the endosomal membrane and the uncoating of the C 
protein. (87-89) RV genomic RNA released into the cytoplasm serves as template for 
the synthesis of the non-structural proteins and a 40S negative-sense RNA strand. (90) 
The 40S negative-polarity RNA functions as a template for the genomic RNA and a 24S 
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sub-genomic RNA encoding the structural proteins. (85, 90)  The non-structural 
proteins and replicating RNA remain in close association with the endosome, and 
stimulate the formation of spherule-like membrane invaginations intruding into the 
lumen of the endosome. (87) The nascent spherules remain attached to the endosomal 
membrane via a neck structure, and provide a protected environment for viral RNA 
replication, and for the synthesis of the non-structural proteins. (84, 85) The 24S 
subgenomic RNA is transported to the rough endoplasmic reticulum (RER), and the 
translated polyprotein precursor is processed by a cellular signalase, leading to the 
formation of the C, E1 and E2 structural proteins. (84, 91) The E1 and E2 glycoproteins 
then become embedded into the ER, and the C protein likewise remains membrane-
associated. (91, 92) After being transported through the Golgi apparatus, the C protein 
reaches the modified endosome, and assembles with the newly synthesized genomic 
RNA expelled from the invaginations. As infection proceeds, the RV-modified 
endosome attracts several intracellular organelles, such as the RER, Golgi apparatus and 
mitochondria, together constituting the replication complex, also termed the RV factory. 
(87, 93, 94) The nucleocapsid of RV then matures via budding through the intracellular 
membrane, including the Golgi complex, ER and cytoplasmic vacuoles, or occasionally 
at the plasma membrane. (92, 94, 95) Together, these findings underscore the ability of 
RV to harness the endomembrane compartment in order to provide optimal conditions 
for almost every step of its replication.  
 
The effect of RV on cell death 
While RV establishes persistent, noncytocidal infection in many cell types, it can also 
trigger apoptotic cell death in some cell lines, such as the BHK21, Vero and RK13. (96-
101) The ability of RV to induce apoptosis varies considerably with cell type and virus 
strain.  (90) The non-structural proteins and C protein may be required for apoptosis 
induction. (96, 98) The non-structural protein p90 was shown to interact with some 
cellular proteins, such as the retinoblastoma tumor suppressor protein (pRb) and citron-
K kinase (CK). (102, 103) The RV p90-pRb and RV p90-CK interactions may interfere 
with the physiological functions of pRb and CK. pRb is a crucial regulator of cell 
division. (104) Thus, the functional perturbation of pRb may dysregulate the G1-S 
phase transition of cell cycle progression, which in turn may lead to the activation of 
p53 and induction of the intrinsic pathway of apoptosis. (105) Indeed, previous in vitro 
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studies revealed a dramatic increase in p53 level, and demonstrated that a dominant-
negative p53 mutant conferred partial protection from RV-induced apoptosis. (100) CK 
is a downstream target of the cellular Rho family small GTPases. The Rho proteins are 
important regulators of cytoplasmic formation of actin structures during cytokinesis. 
(106) Thus, the functional perturbation of CK may block cell cycle progression in the S-
M phase transition, which in turn may lead to the generation of a subpopulation of cells 
with tetraploid nuclei. (106) RV C protein is an essential structural component of the 
virions, and a key factor in virus–host interactions. (107) Transfection studies have 
revealed that the C protein by itself can trigger apoptotic cell death. (96, 98, 99) 
Interaction of C protein with p32 mitochondrial protein regulating the opening of the 
permeability transition pore may play an important role in apoptosis induction. (108) 
Together, these results indicate that RV activates multiple pathways of apoptosis. (98-
103) However, the effect of this virus on other cell death subroutines has not yet been 
investigated. 
 
Pathogenesis and clinical syndromes 
The infection caused by RV in early childhood or adult life is usually mild, self-
limiting, and often asymptomatic. The infection is contracted via the respiratory route. 
RV replicates in the nasopharynx and lungs first, then spreads to the lymph nodes, and 
appears in the blood. The resulting viremia transfers the virus to various tissues and the 
skin. Clinically apparent postnatal rubella is characterized by maculopapular rash, 
lymphadenopathy and fever. (81, 82) The rash is the most prominent feature and exists 
in most of the cases. It begins on the face, and spreads in centripetal fashion. Infection 
in adults can be more severe, and can occasionally be complicated by more significant 
symptoms, such as arthropathy, thrombocytopenia and postinfectious encephalopathy. 
(82, 109, 110)  
In seronegative or immunodeficient pregnant women, the virus can cross the placenta 
and infect the fetus during maternal viremia. RV is capable of spreading widely 
throughout the developing fetus, and almost any organ can be infected. A chronic and 
generally non-cytolytic infection is then established. The embryo is at great risk until 
the 20th week of pregnancy. (90, 111, 112) By disturbing the ontogeny of fetal organs, 
congenital RV infection may lead to serious developmental abnormalities. (90, 111) 
Common clinical manifestations of CRS include congenital heart defects (most 
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frequently patent ductus arteriosus, pulmonary artery or valvular stenosis), cataract, 
glaucoma or retinopathy, hearing loss, psychomotor retardation, skin rash at birth, low 
birth weight and hepatosplenomegaly. (90) Although the teratogenic effect of this virus 
is not yet fully understood, numerous noteworthy studies suggest that the clues lie in the 
unusual features and unique cellular effects of RV replication. (90, 113-116) 
No treatment is available for rubella. (117) The best means of preventing rubella is 
vaccination with a triple vaccine containing live, attenuated measles, mumps and rubella 
viruses (MMR). (81) 
 
III. Herpes simplex viruses and their interaction with the infected cells 
Herpes simplex viruses-1 and -2 (HSV-1 and -2) belong to the Herpesviridae family, 
commonly cause postnatal infections by invading the body through the skin and mucous 
membranes of the orofacial or genital regions. (118) HSV can also be contracted in 
utero, at the time of delivery or postnatally, leading to neonatal infection. (118) 
 
Structure and replication of HSV-1 and HSV-2 
 HSV-1 and HSV-2 particles are 120-200 nm in diameter and have four structural 
elements: (i) the core, (ii) an icosahedral capsid containing 162 capsomeres, (iii) the 
tegument and (iv) an outer envelope with glycoprotein spikes. The core is composed of 
linear double-stranded DNA of the virus. The genomes of HSV-1 and HSV-2 contain 
two covalently-linked sections, termed long unique region (UL) and short unique region 
(US), each of which is bracketed by two sets of inverted repeats of DNA. (118, 119) The 
capsid is made up of four viral proteins, VP5 (gene UL19), VP26 (gene UL35), VP23 
(gene UL18), and VP19C (gene UL38). The capsid also contains UL6 protein, and VP24 
protease (gene UL26) required for the proteolytic processing of scaffold proteins. (118, 
120) The space between the envelope and the capsid is largely unstructured, and it is 
composed of at least 20 viral proteins. The major proteins constituting the tegument are: 
(i) the virion host shutoff factor (gene UL41), (ii) VP16 or α-trans-inducing factor, 
responsible for the transactivation of immediate early (IE) genes (gene UL48), (iii) 
VP22 (gene UL49), (iv) a very large tegument protein (VP1-2; gene UL36) and (v) UL13 
protein kinase. (121,122) The envelope consists of a lipid bilayer with approximately 11 
different viral glycoproteins embedded in it. The virion envelope glycoproteins are gB 
(VP7 and VP8.5), gC (VP8; gene UL44), gD (VP17 and VP18; gene US6), gE (VP12.3 
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and VP12.6; gene US8), gG (gene US4), gH (gene UL22), gI (gene US7), gL (gene UL1), 
and gM (gene UL11). (118)  
The envelope glycoproteins gC and gD play important role in the adsorption of HSV 
virion to cell surface receptors. gC attaches to heparan sulfate, while gD binds to 
herpesvirus entry mediator, nectin-1 and 3-O sulfated heparan sulfate. (123, 124) These 
interactions bring the viral envelope and the cell membrane into close proximity, and 
thereby allow the binding of gH, gL and gB to their corresponding receptors. (125, 126) 
After the fusion of the viral envelope with the plasma membrane, the capsid enters the 
cytoplasm and translocates to the nucleus, where transcription, replication of viral DNA 
and capsid assembly take place. (118, 127, 128) HSV DNA may become circularized by 
cellular DNA repair enzymes, and establish a latent infection within the neurons of the 
sensory ganglia, brain stem, olfactory bulbs and temporal lobe. (129, 130) During 
latency no viral particles are formed, only the latency-associated transcript is expressed, 
and the viral genome is maintained in an episomal state. (131-133) From this cellular 
reservoir, reactivation may occur. (130, 133) In other cell types, viral DNA remains 
linear, and a productive replication cycle ensues. (128) Initially, IE or α genes are 
transcribed, and their protein products transactivate the early or β and late or γ genes. 
(118, 134) By definition, early genes are those viral genes, which are expressed in the 
presence of IE proteins before the onset of DNA replication. (118, 127, 128) The 
products of early genes are primarily implicated in the replication of HSV DNA. (118) 
The late genes encode structural components of the HSV virion. (118) Viral DNA 
replicates in the nucleus by a rolling circle mechanism, leading to the formation of 
concatemeric genomes, which in turn are cleaved and packaged into preformed capsids. 
(135) Following virion maturation, tegumented capsids gain their envelope by budding 
through the Golgi apparatus, and then released from the cell by reverse endocytosis. 
(136)  
 
The effect of HSV-1 and HSV-2 on cell death 
HSV-1 and HSV-2 are capable of infecting different histological types of cells, 
including epithelial cells, fibroblasts, neurons of sensory ganglia and central nervous 
system, lymphocytes, monocytes, and dendritic cells. (118, 137) The fate of infected 
cell largely depends on its histological type. Neurons, in which HSV-1 and HSV-2 
establish latency, survive. Epithelial cells, fibroblasts, monocytes and dendritic cells die 
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primarily by way of necrosis and apoptosis. (138-142) Moreover, both HSV-1 and 
HSV-2 have the capability to modulate the process of autophagy. (140-142) 
Activation of the necrotic cell death subroutine has been revealed in several infections 
caused by HSV-1 and HSV-2, including encephalitis, acute retinal necrosis and 
hepatitis. (143, 144) The mechanism of necrotic tissue damage is complex and involves 
a direct cytopathic effect of HSV and indirect, immune-mediated events.  
HSV-1 and HSV-2 are also capable of modulating the apoptotic cell death pathways. 
Early in infection with HSV-1 or HSV-2, the appearance of viral IE mRNAs activates 
the cellular apoptotic machinery. (132) However, at 3 to 6 hours postinfection (hpi), 
several anti-apoptotic HSV proteins (ICP4, ICP22, ICP17, ICP34.5, US3, US5, US6, 
UL14 and ICP10 of HSV-2), as well as the latency-associated transcript inhibit 
apoptotic demise, and maintain cell survival until the replication cycle is completed. 
The time period while anti-apoptotic HSV proteins are synthesized is termed “apoptosis 
prevention window”. (145) In this phase of infection, the intricate balance of pro- and 
anti-apoptotic factors is strongly biased by the indirect influence of powerful cellular 
defense pathways, such as the DNA damage response pathway or the interferon system. 
(146) Finally, HSV multiplication leads to the inevitable death of host cells, at least in 
part via apoptotic mechanisms. Apoptosis fulfils dual functions in the pathogenic 
mechanism of diseases caused by HSV-1 and HSV-2; it contributes to tissue damage 
and exerts antiviral effect by inhibiting viral spread at the expense of killing infected 
cells. 
HSV-1 and HSV-2 may also affect the autophagic cascade. (147, 148) At the early 
stage of infection, HSV-1 provokes autophagy. (149) However, some viral proteins 
(ICP34.5 and US11) synthesized during the subsequent phases of productive infection 
function as powerful inhibitors of the autophagic process. (147) ICP34.5 of HSV-1 
antagonizes autophagy by binding Beclin-1, and by blocking the double-stranded RNA-
dependent protein kinase/eukaryotic translation initiation factor 2α (PKR/eIF2α) 
pathway. (149, 150, 151) The HSV-1 US11 protein exerts anti-autophagic activity via 
its direct interacion with PKR. (148) These interesting observations have shed light on 
the importance of autophagy in infections caused by HSV-1, as well as successfully 
uncovered the underlying molecular mechanisms in some experimental systems. At 




Pathogenesis and clinical syndromes 
HSV-1 and HSV-2 invade the body through the skin and the mucous membranes of 
the orofacial or genital regions. During initial replication in epithelial tissues, HSV-1 
and HSV-2 infect the sensory and autonomic nerve endings, and the nucleocapsids are 
transported intraaxonally to the nerve cell bodies in ganglia. The trigeminal ganglia are 
infected during the course of orofacial manifestations, while the sacral ganglia are more 
commonly affected in genital diseases. Viral replication takes place in neural tissues 
during primary infections, and eventually, a lifelong latency is established. The primary 
lesions usually heal completely. However, in response to local or systemic stressors, 
activation of productive viral multiplication may occur subsequently. HSV virions are 
then transported along the neuronal axons, back to peripheral tissues to cause recurrent 
lesions. This process is termed reactivation. (118, 152) 
HSV-1 and HSV-2 can cause a variety of mild and severe diseases, including herpes 
simplex labialis, ocular disease, genital herpes, encephalitis and neonatal infection. 
Gingivostomatitis and pharyngitis are the most frequent clinical manifestations of 
orofacial HSV infections, usually involving the lip, tounge, gingiva, palate and face.  
First-episode infections lead to the formation of exulcerating vesicular lesions in the 
epithelia, and the clinical symptoms include pain, itching and fever. Recurrent herpes 
labialis is the most frequent clinical consequence of reactivation. Recurrent herpes 
labialis is associated with feaster healing and less frequent systemic signs than primary 
orofacial herpes. Although both viral types can invade the oral mucosa and lips, HSV-1 
is the predominant causative agent of orofacial herpetic infections. (118, 152) 
Genital herpes is a sexually transmitted disease primarily associated with HSV-2. HSV 
genital tract disease is characterized by local and systemic signs, including pain, itching, 
dysuria, vaginal and urethral discharge, inguinal lymphadenopathy, fever, headache, 
malaise, and myalgias. HSV replicating in external genitalia triggers the development of 
epithelial lesion and intensive inflammatory reaction. The lesions vary in their stages; 
vesicles, pustules, painful erythematous ulcers, crusting, or re-epithelialization can all 
be observed. Occasionally, endometritis, salpingitis and prostatitis may also arise from 
genital HSV infection. Genital herpes is frequently accompanied by local spread and 
systemic complications. The infection frequently extends to the buttock, groin and thigh 
area, and rarely the fingers and the eye can also be involved. HSV-2 may even cause 
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autonomic nervous system dysfunction, transverse myelitis, and meningitis with 
headache, stiff neck and photophobia. (152-154) 
Herpetic eye involvement may manifest clinically as blepharitis, conjunctivitis, 
keratitis, iridocyclitis and acute retinal necrosis. Primary herpetic ocular surface disease 
can develop directly via ‘front-door’ route infection by droplet spread, or via a ‘back-
door’ route, which involves the indirect spread of the HSV to the eye from a non-ocular 
site. Patients with herpetic conjunctivitis typically present with an acutely red eye, a 
watery discharge, conjunctival swelling, and in some cases photophobia and a foreign-
body sensation. Occasionally, patients also exhibit subconjunctival hemorrhage and 
numerous lymphoid follicles on the tarsal conjunctiva. HSV-1 and HSV-2 may infect 
the cornea, leading to epithelial, stromal and endothelial keratitis, respectively. 
Epithelial keratitis can be characterized by the appearance of branching dendritiform, or 
enlarged geographic ulcers. Stromal keratitis and endothelitis can result in stromal 
scarring, thinning, neovascularization, severe iridocyclitis and an elevated intraocular 
pressure. (155, 156) Most cases of corneal ulceration will eventually resolve, though 
recurrent infections impair the corneal function and lead to a vision impairment that 
may even necessitate penetrating keratoplasty. Although HSV-1 continues to be the 
dominant type in ocular infections, HSV-2 also has the capability to invade the eye, and 
even mixed infections with both HSV-1 and HSV-2 can occur. The recent changes in 
behavioral patterns and sexual practices have led to a genital herpes outbreak, therefore 
a growing incidence in the ocular manifestations of HSV-2 infection may emerge in the 
future. (155-159) 
Occasionally, HSV infection may appear in other clinical presentations. Reactivation 
of HSV infection or reinfection with another strain of HSV may cause encephalitis. 
Some visceral organs, such as the esophagus, lung and liver may also be infected with 
HSV, most commonly as part of multi-organ involvement in immunosuppressed 
patients. (152, 154, 160) 
Neonatal herpes is acquired perinatally, congenitally or postnatally in 90%, 8% or 2% 
of the cases, respectively. Perinatal HSV infection usually results from contact with 
HSV-2-infected genital secretions during delivery. Congenital infection occurs in 
infants born to mothers who had primary HSV infection during pregnancy. Infants born 
to seronegative mothers may acquire infection through postnatal contact with 
symptomatic or asymptomatic HSV-1-infected family members or health care workers. 
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Neonatal herpes is severe, and has a tendency for dissemination to the central nervous 
system and visceral organs. (152, 161) 
Several antiviral agents are available for the treatment of HSV infections. Aciclovir 
and its related compounds valaciclovir, penciclovir and famciclovir are the mainstay of 
therapy. Aciclovir (9-[(2-hydroxyethoxy)methyl]-9H-guanine) and penciclovir (9-[4-
hydroxy-3-hydroxymethylbut-1-yl] guanine) are deoxyguanosine analogues. 
Valaciclovir is the l-valyl ester prodrug of aciclovir. Famciclovir is the diacetyl ester 
prodrug of 6-deoxy penciclovir. Following their cellular uptake, aciclovir and its related 
compounds are selectively phosphorylated to monophosphate forms by the thymidine 
kinase (TK) of HSV-1 and HSV-2, present only in infected cells. The drug 
monophosphates are then phosphorylated to triphosphate forms that act as competitive 
inhibitors of viral DNA polymerase. Moreover, aciclovir triphosphate is incorporated 
into the growing DNA chain of HSV, and causes chain termination, while penciclovir is 
not an obligate chain terminator. (118, 162) TK-deficient or TK-altered HSV strains 
may display resistance to these guanosine analogues. Thus, for the treatment of 
infections caused by viral isolates with altered TK cidofovir or foscarnet may be used. 
(162)  
Cidofovir (S)-1-[3-hydroxy-2-(phosphomethoxy) propyl] cytosine dihydrate) is an 
acyclic phosphonate nucleotide analogue of deoxycytidine monophosphate, while 
foscarnet (trisodium phosphonoformate) is an inorganic pyrophosphate derivative. 
Cidofovir is phosphorylated to the active cidofovir diphosphate form by cellular 
enzymes, and thereby it is effective in infections caused by TK-altered HSV strains. 
Cidofovir diphosphate acts as competitive inhibitor of HSV DNA polymerase and chain 
terminator. Foscarnet does not undergo significant intracellular metabolism, instead it 
directly inhibits HSV DNA polymerase via blocking the pyrophosphate binding site on 
the enzyme. The selectivity of foscarnet lies in its greater efficiency against the viral 
DNA polymerase compared with the cellular enzymes. (118, 162, 163) 
To date, no licensed vaccine is available for the prevention of HSV infections; 










I. Investigation of the effect of RV on autophagy in the SIRC cell line 
In an effort to gain more insight into the pathogenic mechanisms of RV infections, we 
set out to investigate viral multiplication, autophagy and apoptosis in RV-infected SIRC 
cell cultures. Our aims were as follows:   
a.) To investigate the susceptibility of the SIRC corneal cell line to RV. 
b.) To study the effect of RV on basal and rapamycin-induced autophagy. 
c.) To measure the autophagic flux in RV-infected cells. 
d.) To analyze the effect of RV on autophagosome formation. 
e.) To study the connection between autophagy and apoptosis in cells infected with RV.  
II. Investigation of the effects of HSV-1 and HSV-2 on autophagy in the SIRC cell line 
In an effort to gain more insight into the pathogenic mechanism of herpetic ocular 
surface disease, we set out to investigate viral multiplication, autophagy and apoptosis 
in cultures infected with HSV-1 or HSV-2. Our aims were as follows: 
a.) To investigate the susceptibility of the SIRC corneal cell line to HSV-1 and HSV-2. 
b.) To study the effects of HSV-1 and HSV-2 on basal autophagy. 
c.) To measure the autophagic flux in cells infected with HSV-1 or HSV-2. 
d.) To analyze the effects of HSV-1 on autophagosome formation. 
e.) To study the connection between autophagy and apoptosis in cells infected with 
HSV-1 or HSV-2. 
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MATERIALS AND METHODS 
Cell cultures 
SIRC cell line: The Statens Seruminstitut Rabbit Cornea (SIRC) cell line (obtained 
from ATCC, code CCL-60), was grown in Dulbecco's modified Eagle's minimal 
essential medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal 
calf serum (Lonza, Verviers, Belgium). 
Vero cell line: The Vero cell line was grown in Dulbecco's modified Eagle's minimal 
essential medium (Sigma-Aldrich) supplemented with 7.5% fetal calf serum (Lonza). 
Both cell lines used were cultured at 37 °C in a 5% CO2 atmosphere. 
Viruses 
HSV: The KOS strain of HSV-1 and the wild-type HSV-2 were propagated at a 
multiplicity of infection (MOI) of 0.001 plaque forming units per cell (PFU/cell) in 
Vero cell cultures for 3 days at 37 °C. The culture fluids of HSV-1- or HSV-2-infected 
Vero cells were harvested, stored at –70 °C, and used as infecting stock of the virus. 
RV: The To336 strain of RV (obtained from ATCC, code VR-553) was propagated at 
an MOI of 0.01 PFU/cell in Vero cell cultures for 7 days at 35 °C. The culture fluid of 
RV-infected Vero cells was harvested, stored at –70 °C, and used as infecting stock of 
the virus. 
Methods used to detect viral replication 
RV: Virus plaque assay was performed on confluent monolayers of Vero cells 
inoculated with virus solution for 1 h at 35 °C and overlaid with 0.5% agarose (FMC, 
Rockland, ME, USA) in phenol red-free Eagle’s minimum essential medium 
supplemented with 7.5% FCS and 2 mM L-glutamine. After 4 days of culturing at 35 
°C, a second agarose overlay containing 0.005% neutral red was added. Plaque titers 
were determined at 7 days postinfection (dpi). 
For experiments, SIRC cell cultures were inoculated with the To336 strain of RV at an 
MOI of 5 PFU/cell. 
HSV-1 and HSV-2: For experiments, SIRC cell cultures were inoculated with the KOS 
strain of HSV-1 or a wild-type strain of HSV-2 at different MOIs. Virus plaque assays 
were performed on confluent monolayers of Vero cells inoculated with one or other 
HSV solution for 1 h at 37 °C and overlaid with 0.5% agarose in phenol red-free Eagle's 
minimum essential medium supplemented with 7.5% FCS and 2 mM L-glutamine. 
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After 2 days of culturing at 37 °C, a second agarose overlay containing 0.005% neutral 
red was added. Plaque titers were determined at 3 dpi. 
Indirect immunofluorescence assay 
Cytospin cell preparations were fixed in methanol-acetone (1:1) for 15 minutes (min) at 
20 °C. The cells were treated with 2% bovine serum albumin in phosphate-buffered 
saline (PBS) for 30 min at 37 °C to block unspecific binding of the antibodies. To detect 
RV glycoprotein E1,  HSV gD and LC3B, the slides were stained with primary 
antibodies for 1 h at 37 °C (Santa Cruz Biotechnology, Inc., Dallas, TX, USA and 
Sigma-Aldrich, respectively) . After washing with PBS, the samples were reacted with 
fluorescein isothiocyanate (FITC)-conjugated or CF640R-labeled species-specific 
antibodies (Sigma-Aldrich) for 1 h at 37˚C. The cells were visualized by confocal 
microscopy using an Olympus FV 1000 confocal laser scanning microscope (Melville, 
NY, USA) or an epifluorescence microscope (Leica Microsystems GmbH, Wetzlar, 
Germany). The ratios of RV- and HSV-infected cells were determined after counting 
1000 cells in random fields. LC3B-positive vacuoles were automatically quantified for 
each field after subtraction of the background level and establishment of an intensity 
threshold by using the Image J software. (167) Both the numbers and the average 
surface areas of the LC3B-positive puncta were normalized to the numbers of cells in 
each field. An average of 780 cells were analyzed for each condition. The fluorescence 
intensity of LC3B was determined by using the line scan analysis function of the Image 
J software. (167) 
Acridin orange (AO) staining 
Cytoplasmic acidification was assessed by the AO staining procedure of the autophagic 
vacuoles. The cells, grown on glass coverslips were incubated for 15 min at 37°C in 
serum-free medium containing 2 µg/ml 3,6-bis(dimethylamine)acridine. After washing 
with PBS, fluorescent micrographs were obtained using an Olympus FV 1000 confocal 
laser scanning microscope (Melville, NY, USA) or an epifluorescence microscope 
(Leica Microsystems GmbH, Wetzlar, Germany). Fluorescence intensities in green, red 
and overlapping spectral regions were determined and analyzed by using an ”apoptosis 
correlator” plugin (168) operated in the Image J software. (167) 
Quantificiation of apoptosis by enzyme-linked immunosorbent assay (ELISA) 
For apoptosis ELISA, the cells were processed in a cell death detection ELISA kit 
(Roche Diagnostics GmbH, Penzberg, Germany). The cells were incubated in lysis 
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buffer for 30 min and centrifuged at 8000 rpm for 10 min. The supernatants were 
transferred into a streptavidin-coated microplate and incubated with biotin-conjugated 
anti-histone and peroxidase-conjugated anti-DNA monoclonal antibodies for 2 h. After 
washing, ABTS substrate solution was added to each well for 15 min. Absorbance was 
measured at 405 and 490 nm. The specific enrichment of mono- and oligonucleosomes 
was calculated as enrichment factor (EF) = absorbance of RV-infected cells/absorbance 
of corresponding noninfected control cells. 
Quantification of apoptosis by Annexin V/Propidium iodide (AN/PI) double 
labeling  
For AN/PI double labeling, the cells were stained with FITC-labeled annexin V (AN-
FITC) and propidium iodide (PI) (MBL, Woburn, MA, USA) according to the 
manufacturer’s instructions. The fluorescence intensities of AN-FITC and PI were 
determined with a BD Bioscience flow cytometer (BD Biosciences, San Diego, CA, 
USA). The percentages of apoptotic cells were calculated by sorting the cells that were 
positive only for AN (early apoptotic stage) or for both AN and PI (late apoptotic or 
secondary necrotic stages). 
Transmission electron microscopy 
Samples were fixed in 0.1 M sodium cacodylate-buffered 2.5% glutaraldehyde solution 
(pH 7.4) for 2 h and then rinsed three times for 10 min each in 0.1 M sodium cacodylate 
buffer and 7.5% saccharose. The samples were post-fixed in 1% OsO4 solution for 1 h. 
After dehydration in an ethanol gradient (70%, 96% and 100% ethanol for 20 min each), 
samples were embedded in Durcupan ACM. Ultrathin sections were stained with uranyl 
acetate and lead citrate. Sections were examined in a Philips CM 10 microscope (Philips 
Electronic Instruments, Mahwah, NJ, USA) at 80 kV. 
Western blot analysis 
Cells were homogenized in CytoBuster lysis buffer (Novagen, EMD Biosciences, 
Darmstadt, Germany), and the mixture was then centrifuged at 10000 g for 10 min to 
remove cell debris. Protein concentrations of cell lysates were determined by using the 
Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Supernatants were mixed with 
Laemmli's sample buffer and boiled for 3 min. Aliquots of the supernatants, containing 
40-50 µg of total protein to detect actin, HSV gD, LC3B and Atg12–Atg5 conjugate 
were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
electrotransferred onto nitrocellulose filters (Bio-Rad). Preblocked blots were reacted 
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with antibodies against actin (Sigma-Aldrich), HSV gD (Sigma-Aldrich), LC3B 
(Sigma-Aldrich) and Atg5 (Santa Cruz Biotechnology, Inc.) for 4 h in PBS containing 
0.05% Tween 20, 1% dried non-fat milk (Difco Laboratories, Detroit, MI, USA) and 
1% BSA (Sigma-Aldrich). Blots were then incubated for 2 h with peroxidase-
conjugated species-specific antibodies (DakoCytomation, Carpinteria, CA, USA). 
Filters were developed by using a chemiluminescence detection system (Thermo Fisher 
Scientific Inc., Rockford, IL, USA). The autoradiographs were scanned with a GS-800 
densitometer (Bio-Rad), and the relative band intensities were quantified by use of the 
ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). 
Statistical analysis 
All values are expressed as mean ± standard deviation (SD). Student’s unpaired t-test or 
the one-way ANOVA test with the Bonferroni post-test were used for pairwise multiple 
comparisons, and P values < 0.05 were considered statistically significant (GraphPad 
Prism 5, GraphPad Software Inc., La Jolla, CA, USA). 
RESULTS 
I. The effect of RV on autophagy in the SIRC cell line 
To elucidate how RV affects the cellular autophagic cascade, (i) the replication 
kinetics of RV, (ii) the levels of LC3B and the Atg12–Atg5 conjugate, (iii) the 
autophagic flux, (iv) the subcellular localization of LC3B and (v) cytoplasmic 
acidification were measured in SIRC cells infected at an MOI of 5. 
I./1. Replication of RV in the SIRC cell line 
Indirect immunofluorescence assays to determine the kinetics of virus 
multiplication revealed positive staining for the E1 envelope glycoprotein of RV on 
days 1, 3 and 5 (Fig. 1a) in 6.2, 42.8 and 69.1 % of the cells, respectively. In good 
accord with previous findings (169), these data indicate that the SIRC cell line is 
highly permissive for RV replication, and the infection proceeds in a slow and 
asynchronous way. 
I./2. The effect of RV on the expression levels of autophagosomal marker proteins 
To study the effects of RV on the basal autophagy, the levels of LC3B-I, LC3B-II 
and the Atg12–Atg5 conjugate were determined by Western blot analysis. The 
mock-infected cells displayed endogenous expression of both the lipidated and the 
non-lipidated forms of LC3B at the 0-day time point, and the LC3B-II levels 
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increased continuously and dramatically throughout the 5-day culture period. (Fig. 
1b; lanes 1-4) In contrast, RV-infected cells exhibited only moderate increases in 
LC3B-II levels at 3 and 5 dpi. (Fig. 1b; lanes 5-8) 
The endogenous expression of the Atg12–Atg5 conjugate in the mock-infected cells 
was slightly downregulated during the 5-day culture period (Fig. 1b; lanes 1-4), 
while RV infection triggered a pronounced decrease in the level of the Atg12–Atg5 
conjugate. (Fig. 1b; lanes 6-8) Thus, RV infection decreases the levels of LC3B-II 
and the Atg12–Atg5 conjugate. 
I./3. The effect of RV on the autophagic flux 
To investigate the autophagic flux in RV-infected cells, LC3B-II levels were 
measured under conditions where autophagosome degradation was blocked by 
bafilomycin A1, a pharmacological inhibitor of autophagosome-lysosome fusion 
and lysosomal hydrolase activity. As bafilomycin A1 exerted cytotoxic effects 
when it was present throughout the infection (data not shown), the cultures were 
infected first and treated with bafilomycin A1 for a 24-h period just before the 
preparation of cell lysates. As expected, bafilomycin A1 elevated the level of 
LC3B-II as compared with the untreated mock-infected cells (Fig. 1c; lanes 4 and 
2, respectively), indicating that this drug efficiently blocked autophagic flux under 
the experimental conditions used. Interestingly, the LC3B-II level of RV-infected 
cells incubated in the presence of bafilomycin A1 was considerably lower than that 




Fig. 1 RV infection decreases the level of autophagic proteins and impedes the autophagix flux. a 
Detection of RV E1 envelope glycoprotein by immunofluorescence assay. Scale bar 10 µm. Values 
on the graph denote mean ± SEM of three independent experiments. b Western blot analysis 
showing the kinetics of endogenous LC3B-II and Atg12-Atg5 conjugate expression. Band intensities 
were quantified by using the ImageQuant Software. The ratios of the protein levels measured on 
days 1, 3 and 5 to that of the corresponding 0-day time point controls were calculated, and expressed 
as fold change, shown below each lane. c Western blot analysis showing reduced autophagic flux in 
RV-infected SIRC cells. Mock- and RV-infected cells were either exposed to 100 nM bafilomycin 
A1 or left untreated. The total protein extracted was analyzed for LC3B expression by Western blot 
analysis. BFLA bafilomycin A1 
 
 I./4. The effect of RV on autophagosome formation 
To study the effects of RV on the intracellular localization of endogenous LC3B 
during basal and rapamycin-induced autophagy, indirect immunofluorescence assay 
was used. As rapamycin exerted cytotoxic effects when it was present throughout 
the infection (data not shown), the cultures were infected first and treated with this 
autophagy inducer for a 24-h period just before the preparation of cell lysates. Both 
mock-infected and rapamycin-treated cells displayed patterns characterized by the 
combination of a diffuse, faint and punctate, bright LC3B staining. (Fig. 2a, c, 
respectively) Accordingly, line scan fluorescence intensity analyses revealed 
numerous robust peaks, which were confluent or more separated in the mock-
infected or rapamycin-treated cells, respectively. (Fig. 2a, c, respectively) In 
contrast, RV-infected cells exhibited very faint cytoplasmic staining with only a 
few bright puncta, and the line scan profile consisted mainly of peaks of low height. 
(Fig. 2b) Moreover, the intensity level of LC3B staining in RV-infected cells 
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treated with rapamycin was much lower than that of the drug control. (Fig. 2d, c, 
respectively) Thus, RV infection inhibits the intracellular redistribution of LC3B 
from the cytoplasm to autophagosomes.  
To further investigate the effects of RV on autophagosome formation, the 
abundance and size of LC3B-positive vesicles were also determined. (Fig. 2e, f) 
The average numbers of LC3B-positive vesicles per cell in the mock-infected and 
rapamycin-treated cultures were 19.76 and 21.89, respectively. (Fig. 2e) In contrast, 
the average numbers of puncta in RV-infected cultures were 12.49 and 12.81 in the 
absence or presence of rapamycin, respectively. (Fig. 2e) Thus, RV infection 
triggers a significant decrease in the accumulation of autophagosomes. (Fig. 2e) 
The average Feret diameters of LC3B-positive vesicles in the mock-infected and 
rapamycin-treated cultures were 657 and 680 nm, respectively. (Fig. 2f) 
Intriguingly, the average diameters of the puncta in the RV-infected cultures when 
cells were incubated with rapamycin or left untreated were 481 or 480 nm, 
respectively. (Fig. 2f) Thus, RV infection elicits a significant decrease in the size of 
the autophagosomes. (Fig. 2f) 
 
Fig. 2 RV infection retards autophagosome formation. SIRC cells were infected with the To336 
strain of RV at an MOI of 5 for 5 days, and the intracellular localization of LC3B and cytoplasmic 
acidification were analyzed. a-d Immunofluorescence assay showing the fluorescence intensity of 
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LC3B-positive autophagosomes. The images were subjected to line scan fluorescence intensity 
analysis by using the Image J software. (167) The graphs depict the intensity values along the 
arrows drawn across the images. a Mock-infected culture; b RV-infected culture; c cells treated with 
rapamycin; d RV-infected culture treated with rapamycin. Scale bar 10 µm. e Immunofluorescence 
assay showing the average number of LC3B-positive autophagosomes. The LC3B-positive 
autophagosomes were automatically quantified by using the Image J software. (167) The values on 
the bar graph denote the mean ± SEM of the results of three independent experiments. P values were 
calculated by the Student’s unpaired t test. *** P < 0.001. f Immunofluorescence assay showing the 
average size of LC3B-positive autophagosomes. The surface area of the LC3B-positive 
autophagosomes was determined by using the Image J software. (167) The values on the bar graph 
denote mean ± SEM of the results of three independent experiments. P values were calculated by the 
Student’s unpaired t test. *** P < 0.001.  g-i Reduced AVO formation in RV-infected cells stained 
with AO. Mock- and RV-infected cells were stained with AO, and images were obtained by 
confocal microscopy. AO accumulated by acidic compartments emits orange fluorescence, whereas 
this metachromatic dye bound to compartments with slightly acidic or neutral pH emits green 
fluorescence. Fluorescence intensities in green, red and overlapping spectral regions were 
determined and analyzed by using an „apoptosis correlator” plugin (168) operated in the Image J 
software. (167) Accordingly, the non-overlapping signals are green or red, while the overlapping 
pixels appear as orange in the correlation plots. Thresholds indicated by dashed lines were chosen 
empirically so as to separate visible fluorescence in both images obtained in green and red spectral 
regions from the dark pixels. The values on the bar graph denote mean ± SEM of the results of five 
independent experiments. P values were calculated by Student’s unpaired t test. * P < 0.05, ** P < 
0.01, *** P < 0.001. Rapa, rapamycin. Scale bar 10 µm. 
 
 
To determine the effects of RV infection on the formation of acidic vesicular 
organelles (AVOs), AO staining was used. In the mock-infected cultures, the 
orange nuclei were round in shape with a homogeneous inner structure, and the 
cytoplasm exhibited bright-red staining with a marked punctate structure. (Fig. 2g) 
In the RV-infected cultures, the nuclei were irregular in shape and size, with a 
heterogeneous inner structure displaying a variable staining pattern, and the 
cytoplasm stained pale-red with faint puncta. (Fig. 2h) Analysis of the fluorescence 
intensities in green, red and overlapping spectral regions revealed a reduction in red 
and an enhancement of orange fluorescence in response to RV infection. (Fig. 2g-i) 
Thus, RV infection inhibits cytoplasmic acidification and blocks the development 
of AVOs. 
I./5. The connection between autophagy and apoptosis in RV-infected cells 
To study how rapamycin-induced autophagy modulates the infectious process of 
RV, we infected cells either directly or in the presence of rapamycin, and measured 
(i) the virus yields and (ii) the extent of apoptosis. 
To determine the effects of rapamycin on the level of autophagy in mock- and RV-
infected cells, LC3B expression was measured by Western blot analysis. With 
regard to its toxicity, rapamycin was added to RV-infected cultures for only 24 h 
just before the preparation of cell lysates. Rapamycin triggered an increase in 
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LC3B-II expression as compared with the mock-infected control. (Fig. 3a; lanes 4 
and 1, respectively) This result, corroborating the data obtained by using 
immunofluorescence analysis (Fig. 2a), indicates that this drug efficiently 
stimulated autophagy under the given experimental conditions, and the autophagic 
pathway controlled by the mTOR is intact in the SIRC cell line. The LC3B-II level 
of RV-infected cultures incubated in the presence of rapamycin was considerably 
lower than that of the drug control. (Fig. 3a; lanes 3 and 2, respectively) Thus, RV 
inhibits rapamycin-induced autophagy. 
Plaque assays to measure virus yields at 5 dpi revealed that the titers of culture 
supernatants harvested from RV-infected cultures incubated in the absence or 
presence of rapamycin were on average 4.0 × 106 or 2.7 × 106 PFU/ml. (Fig. 3b) 
Thus, rapamycin-mediated induction of autophagy inhibits RV multiplication. 
ELISA to quantify the extent of apoptotic DNA fragmentation at 5 dpi 
demonstrated low apoptotic levels in the mock-infected and rapamycin-treated 
cultures; the EFs measured in the absence or presence of rapamycin were 1 or 1.5, 
respectively. (Fig. 3c) Cells infected with RV either directly or in the presence of 
rapamycin displayed highly increased apoptotic rates; the EFs measured in the 
absence or presence of rapamycin were 11.3 or 8.0. (Fig. 3c) Interestingly, the 
apoptotic response of RV-infected cells in the absence of rapamycin was 
significantly higher than that of cells treated with this autophagy inducer. (Fig. 3c) 




Fig. 3 Stimulation of autophagy inhibits viral replication and decreases apoptosis in RV-infected 
cells. a Western blot analysis showing the expression level of LC3B. Mock- and RV-infected cells 
were either exposed to 100 nM rapamycin or left untreated. Band intensities were quantified by 
using the ImageQuant Software, and the fold change is shown below each lane. b Plaque assay 
showing decreased RV plaque titers in response of rapamycin treatment. Values denote mean ± 
SEM of the results of three independent experiments. P values were calculated by the Student’s 
unpaired t test. * P < 0.05. c ELISA showing decreased apoptosis of RV-infected cells in response of 
rapamycin treatment. Apoptosis was detected by measuring the specific mono- and 
oligonucleosomes in the cytoplasm by ELISA. The enrichment factor was calculated as described in 
the „Materials and methods” section. Values denote mean ± SEM of the results of three independent 




II. The effect of HSV-1 and HSV-2 on autophagy in the SIRC cell line 
To elucidate how HSV-1 and HSV-2 affect the cellular autophagic cascade, (i) viral 
replication, (ii) the levels of LC3B and the Atg12–Atg5 conjugate, (iii) the 
autophagic flux, (iv) the subcellular localization of LC3B and (v) cytoplasmic 




II./1. Replication of HSV-1 and HSV-2 in the SIRC cell line  
The SIRC cell line was infected with either the KOS strain of HSV-1 or a wild-type 
HSV-2 strain at various multiplicities. Virus replication was measured by indirect 
immunofluorescence assay, Western blot and plaque titration at 24 hpi. Indirect 
immunofluorescence assay revealed positive staining for gD in 97% and 91% of 
cells infected with HSV-1 or HSV-2, respectively. (Fig. 4A) Western blot analysis 
demonstrated the presence of gD in cultures infected with HSV-1 or HSV-2 at 
MOIs of 0.1, 1 and 10. (Fig. 4B)  
 
Fig.4. Replication of HSV-1 and HSV-2 in SIRC cells. (A) Detection of HSV gD by 
immunofluorescence assay. (B) Detection of HSV gD by Western blot assay.  
 
The production of progeny virus was determined by plaque titration of the culture 
supernatants taken from SIRC cells. Depending on the infectious dose, the level of 
HSV-1 production varied between 2.3 x 105 and 3.1 x 107 PFU/ml. (Table 1) The 
level of HSV-2 production varied between 6.8 x 104 and 3.7 x 107 PFU/ml. (Table 
1) Together, these data demonstrate that the SIRC cell line is permissive for both 
HSV-1 and HSV-2 infection. 
MOI Titer of HSV-1 (PFU/ml) Titer of HSV-2 (PFU/ml) 
0.1 2.3 x 105 6.8 x 104 
1 5.4 x 105 5.2 x 105 
10 3.1 x 107 3.7 x 107 
        Table 1. Viral titers in HSV-1- and HSV-2-infected SIRC cells 
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II./2. The effects of HSV-1 and HSV-2 on basal autophagy 
To study the effects of HSV-1 and HSV-2 on the process of autophagy, SIRC cells 
were infected either with HSV-1 or HSV-2 at an MOI of 1 and analyzed by TEM 
and immunofluorescence assay at 24 hpi. 
TEM examination of the mock-infected culture revealed normal cell morphology. 
(Fig. 5A) In contrast, there were numerous intracytoplasmic vacuoles in HSV-1-
infected cells. (Fig. 5B-D) These vacuolar structures contained amorphous 
materials, organelles or virion particles. (Fig. 5B-D) The vacuoles were dispersed in 
the cytoplasm evenly. (Fig. 5B-D) This finding corresponds to the TEM picture of 
excessive autophagy. This test has also provided experimental proof of ongoing 
viral replication in SIRC cells, as numerous assembled capsids and primarily 
enveloped virions were revealed in the nuclei of infected cells. Some fully matured 
cytoplasmic capsids and virions released from the cell in exocytotic vesicles were 
also detected. (Fig. 5B) 
 
Fig. 5 HSV-1 infection increases the formation of autophagic vacuoles in SIRC cells. (A-D) 
Formation of autophagic vacuoles as assessed by TEM. (A) Mock-infected cells; (B, C and D) cells 
infected with HSV-1. Red and green arrows indicate autophagic vacuoles and viral particles, 
respectively. (E and F) Immunofluorescence assay for localization of Atg5. (E) Mock-infected cells; 
(F) cells infected with HSV-1. (G and H) Immunofluorescence assay for localization of LC3B. (G) 
Mock-infected cells; (H) cells infected with HSV-1. 
Indirect immunofluorescence assay to investigate the effect of HSV-1 on the 
intracellular localization of Atg5 and LC3B revealed diffuse, cytoplasmic staining 
patterns in the mock-infected cultures. (Fig. 5E and G, respectively) In contrast, 
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HSV-1 increased the intensity of staining and triggered translocation of Atg5 and 
LC3B from the cytoplasm to distinct puncta in 67% and 93% of cells, respectively. 
(Fig. 5F and H, respectively) Together, these data demonstrate that HSV-1 triggers 
the formation of autophagosomes and alters the intracellular localization of Atg5 
and LC3B. 
II./3. The effects of HSV-1 and HSV-2 on the autophagic flux 
To investigate the autophagic flux, bafilomycin A1 was used as a pharmacological 
tool to inhibit lysosomal degradative activity and to prevent fusion of 
autophagosomes with lysosomes. As bafilomycin A1 decreased the production of 
infectious virions severely when it was present throughout the infection (data not 
shown), an experimental strategy that allows adsorption and uncoating to proceed 
undisturbed was applied. (Fig. 6A) (170) The cells were infected either with HSV-1 
or HSV-2 at an MOI of 20, and incubated for 3 h. The cultures were then treated 
with bafilomycin A1 for an additional 12 h period, and analyzed for viral yields, 
apoptosis and LC3B expression. (Fig. 6A) Western blot analysis to quantify 
intracellular gD protein revealed two bands migrating near 52 and 56 kDa in HSV-
1- or HSV-2-infected cells. (Fig. 6B) This result is fully consistent with previous 
observations demonstrating that gD migrates as a doublet; the ~52 and ~56 kDa 
polypeptides correspond to the non-glycosylated and fully glycosylated forms of 
gD, respectively. (171-173) Bafilomycin A1 inhibited the accumulation of this 
envelope glycoprotein in HSV-1- or HSV-2-infected cells by 12.3% and 42.5%, 
respectively. (Fig. 6B) Plaque assay to quantify viral multiplication revealed that 
bafilomycin A1 retarded replication of HSV-1 and HSV-2 by 52.6% and 13.6%, 
respectively. (Fig. 6C) Thus, the strategy involving delayed addition of bafilomycin 
A1 provided conditions when productive infection has occurred, though at 
diminished levels compared to infected cultures incubated in the absence of this 
autophagy inhibitor.  
Western blot analysis to measure the levels of the lipidated and non-lipidated forms 
of LC3B demonstrated that the mock-infected culture displayed endogenous 
expression both of LC3B-II and LC3B-I; the LC3B-II / LC3B-I ratio was 0.17 at 15 
h of culturing. (Fig. 6D, lane 6) Cells infected with HSV-1 and HSV-2 displayed 
elevated LC3B-II and depressed LC3B-I levels; the LC3B-II / LC3B-I ratios were 
0.82 and 0.56, respectively. (Fig. 6D, lane 2 and 4, respectively) This result 
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demonstrates that HSV-1 and HSV-2 promote LC3B lipidation. Bafilomycin A1 
highly elevated the level of LC3B-II (Fig. 6D, lane 1), indicating that this drug 
efficiently blocked autophagy under the experimental conditions used, and the 
pathways promoting LC3B-II accumulation are intact in the SIRC cell line. In the 
presence of bafilomycin A1, HSV-1 and HSV-2 triggered slightly lower increase in 
the level of LC3B-II than that observed in the corresponding drug control. (Fig. 6D, 
lane 3, 5 and 1, respectively) Thus, both HSV-1 and HSV-2 decrease the 
autophagic flux to some extent. 
 
Fig. 6 HSV-1 and HSV-2 trigger LC3B lipidation, without increasing the autophagic flux. (A) 
Graphical scheme of the experiments designed to assess autophagic flux. (B) Detection of HSV gD 
and actin by Western blot assay. Relative densities of HSV gD and actin were measured by 
densitometric analysis of western blots. HSV gD was normalized to actin, percentage changes of gD 
levels in HSV-infected cells incubated with BFLA were compared to infected controls incubated in 
the absence of BFLA, and the results are presented in graph form below the image. (C) Detection of 
viral yield by plaque assay. (D) Detection of LC3B and actin by Western blot assay. Relative 
densities of LC3B-I, LC3B-II and actin were measured by densitometric analysis of western blots. 
LC3B-I and LC3B-II were normalized to actin, and the LC3B-II to LC3B-I ratio is shown below 
each lane.  
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II./4. The effects of HSV-1 and HSV-2 on the formation of acidic vesicular  
          organelles 
Acridine orange staining to detect AVOs revealed green cytoplasmic and nuclear 
staining in the mock-infected cells at 24 h of culturing. (Fig. 7A) The nuclei of 
mock-infected cells were mostly round in shape. (Fig. 7A) In contrast, cells 
infected with HSV-1 or HSV-2 at an MOI of 1 displayed green nuclear and strong 
red cytoplasmic fluorescence at 24 hpi, demonstrating that both HSV types promote 
cytoplasmic acidification. (Fig. 7A) In HSV-1-infected cultures a few small 
syncytia, containing <5 nuclei, were observed, while HSV-2 infection resulted in 
the formation of numerous large multinucleated giant cells, which contained >50 
nuclei. (Fig. 7A) The nuclei of infected cells had markedly irregular shape, 
contained disorganized chromatin structures, and in some areas blurring, folding or 
complete disruption of the nuclear membrane was also observed. (Fig. 7A) Thus, 
HSV-1 and HSV-2 trigger the development of AVOs. 
 
Fig. 7 HSV-1 and HSV-2 trigger cytoplasmic acidification and excessive cell death in SIRC cells. 
(A) Intracellular pH as assessed by acridine orange staining. (B) Cell death pattern as assessed by 
AN/PI double labelling. The fluorescence intensities of AN-FITC and PI were determined by flow 
cytometry. The two grpahs show superimposed dot plots of fluorescence intensities either of HSV-1 
or HSV-2 and mock-infected cells. 
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II./5. The connection between autophagy and apoptosis in cells infected with   
HSV-  1 or  HSV-2 
To investigate the cytopathogenicity of HSV-1 and HSV-2 in SIRC cultures, the 
cell death pattern of cultures infected at an MOI of 1 was determined by AN / PI 
double labeling at 24 hpi. 
Both HSV-1 and HSV-2 decreased the proportions of viable cells by 32.9% and 
57.8%, respectively. (Fig. 7B) The proportions of AN-single-positive (early 
apoptotic) and double positive (late apoptotic or secondary necrotic) cells in HSV-
1-infected cultures were increased by 15.4% and 13.3%, respectively. (Fig. 7B) The 
proportions of double-positive and PI single positive (necrotic) cells were increased 
by 36.5% and 23.8% in HSV-2-infected cultures, respectively. (Fig. 7B) Together, 
these data reveal that both HSV-1 and HSV-2 trigger extensive cell demise. 
To investigate the potential connection between autophagy and apoptosis, the effect 
of the autophagy inhibitor bafilomycin A1 was assessed. The cells were infected 
either with HSV-1 or HSV-2 at an MOI of 20, and incubated for 3 h. The cultures 
were then treated with bafilomycin A1 for an additional 12 h period, and analyzed 
for apoptosis by ELISA. The assay revealed significantly higher apoptotic rates in 
HSV-1- and HSV-2-infected cells; 1 the EFs for HSV-1 and HSV-2 were 2.86 and 
2.93, respectively. (Fig. 8) EFs for the HSV-1- and HSV-2-infected cells incubated 
in the presence of bafilomycin A1 were 6.36 and 4.32 vs. 2.86 and 2.93 for the 
HSV-1- and HSV-2-infected cells incubated in the absence of drug, respectively. 
(Fig. 8) Thus, bafilomycin A1 triggered a significant increase in the apoptotic 
responses of HSV-1- and HSV-2-infected cells as compared with the corresponding 
infected controls incubated in the absence of drug. Moreover, there was a 
significant difference between the apoptosis inducing activities of HSV-1 and HSV-
2 in bafilomycin A1-treated cells. (Fig. 8) Together, these results demonstrate that 
inhibition of autophagy facilitates apoptosis induced by HSV-1 and HSV-2. 
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Fig. 8 Bafilomycin A1 decreases apoptosis in HSV-1- and HSV-2-infected cells. Apoptosis was 
detected by ELISA. The enrichment factor was calculated as described in the “Materials and 
methods”. Data are mean (±SD) values from three independent experiments. P values were 
calculated by the ANOVA test with the Bonferroni post-test. a p< 0.001 vs Mock; bp<0.001 vs 




I. The effect of RV on the process of autophagy 
Positive-stranded RNA viruses, including several members of the Picornaviridae, 
Flaviviridae and Togaviridae families, have been shown to promote the generation 
and accumulation of autophagosomes in the infected cells. (174) A great body of 
experimental evidence indicates that poliovirus, coxsackievirus B3, human 
rhinovirus 2, enterovirus 71, hepatitis C virus, dengue virus and Japanese 
encephalitis virus induce and actively exploit autophagy to promote their own 
replication. (175-181) Further interesting studies have revealed that chikungunya 
virus, belonging in the Alphavirus genus in the family Togaviridae, elicits ER stress 
and oxidative damage, which in turn activate autophagy via the inositol-requiring 
enzyme 1α/X-boxbinding protein 1 (IRE1α/XBP1) pathway in conjunction with 
mTOR inhibition. (182, 183) Although the autophagy induced by chikungunya 
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virus facilitates viral replication, it delays apoptotic cell demise and mortality after 
infection. (183,184) Thus, autophagy has a protective role in the pathogenesis of 
acute chikungunya disease. (182-186) Another alphavirus, sindbis virus, has been 
shown to activate selective autophagy that involves p62/SQSTM1-Sma and Mad-
related family ubiquitin regulatory factor 1 (SMURF1)-mediated targeting of capsid 
protein and assembled nucleocapsids for autophagic degradation. (187) Sindbis 
virus-induced selective autophagy has been demonstrated to be insufficient to 
restrain the robust viral multiplication, possibly in consequence of its overwhelmed 
clearance capacity. (188,  189) However, the autophagic removal of capsid protein 
aggregates and excess nucleocapsids significantly decreases Sindbis virus-induced 
cell death and dramatically improves the survival of the infected animals.  (188) 
Our study has provided evidence that, unlike alphaviruses and several other 
positive-stranded RNA viruses, the To336 strain of RV inhibits autophagy. 
Initially, four distinct criteria of perturbed autophagy were evaluated in RV-
infected SIRC cells. As the phosphatidylethanolamine-conjugated form of LC3B 
and the Atg12–Atg5 complex are the best-characterized markers of autophagic 
activity (190) the levels of these components of autophagy were measured by 
Western blot analysis. The data revealed that RV infection decreased LC3B-II 
accumulation in comparison with the corresponding mock-infected control (Fig. 
1b), and this was accompanied by a decrease in the Atg12–Atg5 conjugate level at 
3 and 5 dpi (Fig. 1b). The autophagic flux was also assessed by monitoring the 
LC3B-II levels in mock- and RV -infected cultures incubated in the presence of the 
vacuolar H+-ATPase inhibitor bafilomycin A1. In the presence of bafilomycin A1, 
the LC3B-II level of RV-infected cells was substantially lower than that seen in the 
drug control (Fig. 1c), demonstrating that the autophagic flux was markedly 
reduced by this virus. Additionally, high-resolution confocal imaging was 
performed to evaluate autophagosome formation. These experiments revealed that 
RV suppressed the intensity level of LC3B staining, and triggered significant 
decreases in both the number and the average surface area of the autophagosomes 
(Fig. 2a–f), suggesting that this virus inhibits the development of autophagosomes. 
Finally, the effect of RV on AVO formation was determined by using AO staining. 
The results demonstrated that RV infection inhibits cytoplasmic acidification and 
impedes the development of AVOs (Fig. 2g–i). Previous interesting observations 
have clearly demonstrated that an active autophagy flux requires the covalent 
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attachment of Atg12 to Atg5, and in the absence of this linkage, autophagy cannot 
proceed. (190) Further studies have also revealed that defects in LC3 function lead 
to the failure of autophagosome closure. (191)  
In view of these findings, our present results are generally consistent with a 
scenario in which an RV-induced decrease in the level of the Atg12–Atg5 
conjugate impairs LC3B lipidation, which in turn may perturb autophagosome 
formation in RV-infected cells. Another interesting earlier study found that RV 
increases the phosphorylation of Akt and its downstream effector molecules, 
phosphoprotein 70 ribosomal protein S6 kinase (p70S6K) and glycogen synthase 
kinase 3β (GSK3β). (192) Moreover, the inhibition of PI3K by using LY294002 
resulted in increases in the speed and magnitude of RV-induced apoptosis in the 
RK-13 cell line. (192) It is now widely accepted that Akt activates mTOR complex 
1 (mTORC1) by inhibiting two known cellular mTORC1 inhibitors [tuberous 
sclerosis complex 2 (TSC2) and the proline-rich Akt substrate of 40 kDa 
(PRAS40)], thereby stimulating cap-dependent translation, promoting cell survival 
and inhibiting autophagy.  (193-196) Thus, it is reasonable to infer that activation 
of the PI3K/Akt/mTOR axis of signaling may play some role in the inhibition of 
autophagy in RV-infected cells. 
Since some viruses benefit from autophagy, whereas others are harmed, next the 
effect of autophagy induction on RV multiplication was evaluated. Viral titers of 
culture supernatants harvested from RV-infected cultures incubated in the absence 
or presence of rapamycin were measured by plaque assay. The significantly 
reduced viral yield seen in the presence of rapamycin (Fig. 3b) suggested that 
autophagy can control RV multiplication to some extent. The premature death of 
infected cells by way of apoptosis can function as an important antiviral 
mechanism, especially in the case of a virus which is characterized by a slow 
replication kinetics, such as RV (Fig. 1a). (81, 99, 100) As autophagy was shown to 
operate as a facilitator, cooperator or antagonist of apoptosis, depending on the 
nature of the environmental cue and the cellular context (197), the effect of 
autophagy induction on the apoptotic responses of infected cells was evaluated. The 
experiments clearly indicated that RV triggered apoptosis in SIRC cells, and the 
extent of cell demise induced by this virus was significantly reduced by the 
induction of autophagy (Fig. 3c). Thus, these data lend support to the view that 
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autophagy is an efficient antiviral mechanism that does not involve apoptosis 
induction in RV-infected cells. 
Overall, these results suggest that RV employs a strategy to cope with autophagy 
that is totally different from that evolved by other positive-stranded RNA viruses, 
and there is a considerable heterogeneity among the members of the Togaviridae 
family in terms of their effects on the cellular autophagic cascade. Besides its 
cytoprotective effects, autophagy furnishes an important antiviral mechanism, 
inhibition of which may reorchestrate the intracellular environment so as to better 
serve the unique requirements of RV replication. Moreover, the RV-mediated 
inhibition of autophagy may be implicated in the pathogenesis of the congenital 
rubella syndrome, as functional autophagic machinery is of pivotal importance for 
normal fetal development. (198) 
II. The effects of HSV-1 and HSV-2 on the process of autophagy  
DNA viruses, including several members of the Herpesviridae family have been 
shown to modulate the process of autophagy in the infected cells. (148, 199-201) 
Previous studies have demonstrated that the effect of HSV-1 on autophagy is cell-
type-specific. While HSV-1 activates the STING (stimulator of interferon genes)-
dependent autophagy pathway in murine macrophages and dendritic cells, 
neuroblastoma cells respond to HSV-1 infection with an abortive autophagy, and 
the anti-autophagic effects of ICP34.5 and Us11 proteins dominate in fibroblasts 
and primary murine neurons. (148-150, 199, 202) Further interesting studies have 
revealed that varicella-zoster virus, lacking genes encoding anti-autophagic 
proteins, activates autophagy in vitro and in zoster vesicles. (203) A great body of 
experimental evidence also indicates that human cytomegalovirus (CMV) enhances 
some specific steps in the autophagic cascade, while it inhibits others. (201) During 
the first hours of infection, CMV stimulates autophagy in the absence of de novo 
synthesis of viral proteins, and thereby leads to increased expression and lipidation 
of LC3B. (147) However, at later stages of infection, CMV blocks the autophagic 
cascade via stimulating mTOR and inhibiting PKR, and thereby triggers a dramatic 
decrease in the number of autophagosomes. (201, 204, 205) Other remarkable 
studies demonstrate that Epstein-Barr virus (EBV) modulates the unfolded protein 
response (UPR) and autophagy in a coordinated fashion so as to foster the latent 
form of its life cycle. (206) The latent membrane protein 1 (LMP-1) activates the 
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signaling pathway coupled to CD40, essential for proliferation of EBV-infected B 
lymphocytes. LMP-1 triggers UPR dose dependently, which in turn evokes (i) an 
increase in the expression of LMP-1 protein of EBV, (ii) a general block in cellular 
protein synthesis, (iii) induction of apoptotic cell demise and (iv) stimulation of the 
autophagic cascade. Once activated, autophagy facilitates degradation of LMP-1, 
and thereby promotes reconciliation of the diverse cellular response to restore the 
physiological state of cells. Taken together, the available data suggest that 
modulation of autophagy by viruses belonging to the Herpesviridae family plays 
important role in the infectious process, and functions as part of their immune 
escape strategies. However, the precise biological importance of autophagy in the 
pathogenic mechanisms of infections caused by these viruses is not yet fully 
understood. 
Our study has provided evidence that HSV-1 facilitates the accumulation of 
autophagosomes (Fig. 5B-D), as well as the recruitment of LC3B and Atg5 to 
autophagic vacuoles in the SIRC cell line (Fig. 5E and G). Our further experiments 
have also shown that both HSV-1 and HSV-2 trigger LC3B lipidation (Fig. 6D, 
lane 2 and 4), and increase cytoplasmic acidification (Fig. 7A), without enhancing 
the autophagic flux. Together, these results demonstrate that autophagy is induced 
by both HSV-1 and HSV-2 in spite of their effective anti-autophagic 
armamentarium, which possibly impedes the process considerably via inhibiting the 
fusion of autophagosomes with lysosomes. 
Apoptosis has already been implicated in the maintenance of ocular surface 
integrity both in physiological and pathological conditions. (207-210) Compelling 
evidence indicated that apoptosis is instrumental in glaucoma, retinitis pigmentosa, 
cataract, retinoblastoma, retinal ischemia, diabetic retinopathy and several eye 
infections caused by viruses, bacteria, fungi and some protozoans. (208, 211-215) 
Further remarkable studies focusing on the function of corneal keratocytes in the 
maintenance of visual integrity have clearly demonstrated that keratocytes, located 
in the corneal stroma as a highly interconnected cellular network, undergo apoptotic 
cell demise immediately after infections. (208, 216) The apoptotic response of 
keratocytes was shown to operate as an important antiviral mechanism by inhibiting 
the spread of viruses to deeper structures of the eye, and minimizes the 
inflammation that accompanies corneal injury.  (208, 217-219) In full accord with 
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these findings our data have corroborated that both HSV-1 and HSV-2 trigger 
apoptosis in corneal cells (Fig. 7B and Fig. 8). 
Recent findings demonstrated that the apoptotic, autophagic and necrotic pathways 
are interconnected and subject to coordinated regulation. (220) Autophagy can 
operate as antagonist, facilitator or cooperator of apoptosis depending on the nature 
of stressor and cellular context. (220) It has also been shown that HSV-1 elicits an 
mTOR-independent pathway of autophagy, which in turn prolongs survival of 
U251 glioma cells by counteracting the coinciding apoptotic response. (221) Thus, 
next we have asked whether autophagy has the potential to modulate apoptotic 
demise during the course of HSV-1 and HSV-2 infection. Our results have revealed 
that apoptotic cell demise induced by both HSV-1 and HSV-2 is markedly 
enhanced by inhibition of autophagy (Fig. 8) indicating that autophagy acts as 
antagonist of apoptosis in HSV infected SIRC cells. Induction of autophagy by 
HSV-1 and HSV-2 may represent a viral strategy to provide sufficient time for 
replication via inhibiting untimely apoptotic demise. These data corroborate 
previous findings obtained with HSV-1-infected U251 glioma cultures (221), and 
extend the spectrum of cells in which HSV mediated induction of autophagy 
alleviates apoptosis. Under circumstances when apoptosis is blocked, viral 
replication can proceed in an undisturbed fashion, and the inevitable demise of 
HSV-infected cells may preferably occur by way of necrosis. This type of cell death 
may trigger a strong proinflammatory response and thereby it may contribute to the 
development of characteristic clinical symptoms seen in keratitis patients. Together, 
these results may bear on keratitis, since dysregulation of keratocyte apoptosis may 
account for the structural and functional damage of cornea occurring during the 
course of HSV infection. Moreover, our further observation demonstrating a more 
remarkable anti-apoptotic effect of autophagy in cultures infected with HSV-1 than 
in HSV-2-infected cells suggests that the mechanism of corneal cytopathogenicity 
evoked by the two HSV types might involve some different molecular mechanisms. 
A better understanding of intrinsic autophagy evolving during the course of herpes 
simplex keratitis and other infections caused by HSV-1 and HSV-2 may provide 
useful knowledge for the development of novel therapeutic modalities acting 
through autophagy modulation. A recent interesting study revealed that rapamycin 
used topically in a mouse model of HSK suppressed inflammation and 
neovascularization. (222) In view of our present findings obtained by using an in 
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vitro SIRC corneal cell model system, it is reasonable to infer that the beneficial 
therapeutic efficiency of autophagy inducers in herpetic keratitis may partly be due 
to their ability to reduce tissue damage via counteracting apoptotic demise of 
infected cells. 
Overall, our study demonstrates that HSV-1 and HSV-2 affect autophagy and 
apoptosis in a coordinated fashion, and autophagy antagonizes apoptosis in HSV-
infected cells. Together these data implicate autophagy in the pathogenic 
mechanisms of herpetic keratitis. 
 
The following of our results are considered novel 
• RV inhibits autophagy in SIRC cell line. 
• RV blocks the autophagic flux. 
• RV inhibits the development of autophagosomes. 
• RV inhibits cytoplasmic acidification.  
• Activation of autophagy inhibits RV-mediated induction of apoptosis. 
• HSV-1 facilitates the accumulation of autophagosomes, as well as the 
recruitment of LC3B and Atg5 to autophagic vacoules in the SIRC cell line. 
• HSV-1 and HSV-2 stimulate autophagy, without increasing the 
autophagic flux in the SIRC cell line. 
• HSV-1 facilitates the accumulation of autophagosomes. 
• HSV-1 and HSV-2 increase cytoplasmic acidification. 
• Inhibition of autophagy enhances apoptosis triggered by HSV-1 and 
HSV-2. 
SUMMARY 
Autophagy and apoptosis function as important early cellular defense mechanisms in 
infections and other diseases. The outcome of an infection is determined by a complex 
interplay between the pathogenic microorganism and these intracellular pathways. To 
better understand the cytopathogenicity of RV, HSV-1 and HSV-2, we have studied 
the effect of these viruses on the autophagic and apoptotic processes in the SIRC 
corneal cell line.  
Infection with the To336 strain of RV lowered the levels of LC3B-II and the Atg12–
Atg5 conjugate, inhibited the autophagic flux, suppressed the intracellular 
redistribution of LC3B, decreased both the average number and the size of 
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autophagosomes per cell, and impeded the formation of acidic vesicular organelles. 
Induction of autophagy by using rapamycin decreased both the viral yields and the 
apoptotic rates of infected cultures. Thus, besides its cytoprotective effects, autophagy 
furnishes an important anti-viral mechanism, inhibition of which may reorchestrate 
intracellular environment so as to better serve the unique requirements of RV 
replication. Together, these data suggest that RV utilizes a totally different strategy to 
cope with autophagy than that evolved by other positive-stranded RNA viruses, and 
there is considerable heterogeneity among the members of the Togaviridae family in 
terms of their effects on the cellular autophagic cascade. The RV-mediated inhibition 
of autophagy may be implicated in the pathogenesis of the congenital rubella 
syndrome, as functional autophagic machinery is of pivotal importance for normal 
fetal development. 
Infection with the KOS strain of HSV-1 and a wild-type strain of HSV-2 enhanced 
autophagosome formation, triggered cytoplasmic acidification, increased LC3B 
lipidation and elevated the ratio of apoptotic cells. The autophagy inhibitor 
bafilomycin A1 triggered a significant increase in the apoptotic responses of HSV-1- 
and HSV-2-infected cells. Thus, both HSV types affect autophagy and apoptosis in a 
coordinated fashion, and autophagy plays cytoprotective role in HSV-infected cells via 
antagonizing apoptosis. Induction of autophagy by HSV-1 and HSV-2 may represent a 
viral strategy to provide sufficient time for replication via inhibiting untimely 
apoptotic demise. Together these data implicate autophagy in the pathogenic 




A vírusok szaporodásuk során számos intracelluláris folyamat működését 
befolyásolják. Ezen változások különféle programozott sejthalál formák aktiválódását 
eredményezhetik. Vírusfertőzések során az apoptózis, az anoikis, a nekroptózis, a 
partanatosz, a piroptózis és az autofágia indukcióját írták le.  
Az autofágia finoman szabályozott lebontó folyamat, mely eltávolítja és elemeire 
bontja a károsodott sejtalkotókat és fehérjéket. Intracelluláris mikroorganizmusok 
megsemmisítését is végzi, ez esetben a folyamatot xenofágiának nevezik. Az autofágia 
során az eltávolítandó sejtkomponensek, mikroorganizmusok az autofagoszómába 
kerülnek, ami a lizoszómával való fúzióját követően autolizoszómává alakul. A 
vezikulatartalom a lizoszómális enzimek hatására lebomlik. Az autofagoszóma 
kialakulásában fontos szerepet játszik az Atg5, Atg12 és Atg16L proteinek által 
alkotott, 800 kDa molekulatömegű szuperkomplex, valamint az LC3B ubikvitinszerű 
fehérje. Az autofagoszóma kialakulása során először az Atg4 cisztein proteáz a pro-
LC3B-t LC3B-I-re hasítja. Az LC3B-I-hez az Atg5/Atg12/Atg16L komplex 
foszfatidil-etanolamint kapcsol, és így jön létre az LC3B-II, ami nélkülözhetetlen az 
autofagoszóma membrán felépüléséhez.  
A vírusok autofágiára gyakorolt hatása még nem kellően tisztázott. Vizsgálataink 
során ezért a rubeolavírus és a herpes simplex vírusok autofágiás folyamatokra 
gyakorolt hatásait tanulmányoztuk in vitro SIRC corneális sejtvonalon.  
A rubeolavírus autofágiára gyakorolt hatása 
Munkánk kezdeti szakaszában indirekt immunfluoreszencia és plakk titrálás 
segítségével megállapítottuk, hogy a SIRC sejtvonal fogékony a rubeolavírus 
fertőzésre. 
Ezt követően western blot analízissel tanulmányoztuk az LC3B-I és -II proteinek 
valamint az Atg5–Atg12 komplex szintjét. A fertőzetlen kultúrákban a 0. napon az 
LC3B mindkét formája kimutatható volt, és az LC3B-II szintje jelentős emelkedést 
mutatott a kontroll 1., 3., és 5. napos mintáiban. Ezen adat bizonyította a bazális 
autofágia aktiválódását a kontroll sejtekben. Ezzel szemben, a vírussal fertőzött 
kultúrákban az LC3B-II szintjének csak kismértékű emelkedését tudtuk detektálni a 
fertőzést követő 3. és 5. napon. A kontroll minták endogén Atg5–Atg12 expressziója 
kismértékű csökkenést mutatott, míg a vírusfertőzés hatására az Atg5–Atg12 komplex 
szintje nagymértékben csökkent a vírusfertőzéssel párhuzamosan. A rubeolavírus tehát 
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nagymértékben csökkenti az Atg5–Atg12 fehérje szintjét és gátolja az LC3B-I 
lipidációját. 
Az autofágiás-fluxus vizsgálatára irodalmi adatoknak megfelelően bafilomycin A1 
kezelést alkalmaztunk. Megállapítottuk, hogy a vírussal fertőzött és bafilomycin A1-
gyel kezelt mintákban a lipidált LC3B szintje alacsonyabb volt, mint a bafilomycin A1 
kontrollé. A rubeolavírus tehát gátolja az autofágiás fluxust.  
Az LC3B intracelluláris lokalizációját indirekt immunfluoreszcenciás vizsgálat 
segítségével tanulmányoztuk bazális és rapamycin-indukálta autofágia során. Az 
intracelluláris LC3B eloszlás, LC3B-I és LC3B-II esetében különbözik. Az LC3B-I a 
citoplazmában szabadon található meg, immunfestés során diffúz citoplazmafestődést 
láthatunk, míg lipidációt követően az LC3B-II beépül az autofagoszómák 
membránjába. Eredményeink szerint mind a kontroll, mind pedig a rapamycinnel 
kezelt sejtekben intenzív, pöttyözött LC3B festődés volt kimutatható az 5 napos 
kultúrákban; a számos nagyméretű autofagoszóma jelenlétének köszönhetően. Ezzel 
szemben a vírussal fertőzött mintákban, illetve a vírussal fertőzött és rapamycinnel 
kezelt kultúrákban lényegesen kevesebb autofagoszóma volt detektálható. A festődés 
intenzitását line scan analízissel kvantitáltuk. Mérési adataink bizonyították, hogy a 
kontroll és rapamycinnel kezelt mintákban számos erőteljes csúcs található, míg a 
vírusfertőzött illetve vírusfertőzött és rapamycin-kezelt mintákban sokkal kevesebb és 
kisebb intenzitású csúcs van jelen. A rubeolavírus tehát gátolja az LC3B lipidációját, 
és ezáltal az autofagoszómákba történő transzlokációját. ImageJ software segítségével 
meghatároztuk a vakuolumok számát és méretét. Az átlagos vakuolumszám a kontroll 
sejtek esetében 19,76, a rapamycinnel kezelt kultúrákban pedig 21,89 volt. A vírussal 
kezelt sejtekben az átlagos autofagoszómaszám 12,49, míg a vírussal-fertőzött és 
rapamycinnel kezelt kultúrákban 12,81 volt. A rubeolavírus tehát csökkenti az 
autofagoszómák számát. Az átlagos vakuolum átmérő a kontroll sejtek esetében 657 
nm, a rapamycinnel kezelt kultúrákban 680 nm volt. A vírussal kezelt sejtekben az 
autofagoszómák átlagos átmérője 481, míg a vírussal-fertőzött és rapamycinnel kezelt 
kultúrákban 480 nm volt. Érdekes módon a rubeolavírus az autophagosomák átmérőjét 
is csökkenti. 
Az autofagoszómák lizoszómákkal való fúziójának köszönhetően autofágia során a 
citoplazma pH-ja savi irányba tolódik. A citoplazmatikus acidifikációt acridin orange 
festés segítségével vizsgáltuk. Az acridine orange savi pH-nál piros, míg neutrális pH-
nál zöld színű. A kontroll sejtek citoplazmájában intenzív, punktált piros festődés volt 
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látható, míg a vírusfertőzött sejtekben a festődés intenzitása és az acidotikus 
vezikuláris organellumok száma is csökkent. A kontroll kultúrákban, a különböző 
spektrális tartományokban mért festődési intenzitások megoszlása a piros szín 
esetében 49%, a narancs szín esetében 50.6%, a zöld szín esetében pedig 0,4% volt. A 
vírusfertőzött sejtekben, a festődési intenzitások megoszlása a piros szín esetében 
13%, a narancs szín esetében 84%, a zöld szín esetében pedig 3% volt. A rubeolavírus 
tehát jelentősen csökkenti az acidotikus vezikuláris organellumok számát a fertőzött 
sejtekben.    
Végül tanulmányoztuk azt is, hogy az autofágia milyen hatást gyakorol a vírus 
fertőzés folyamatára. Rapamycin alkalmazásával indukáltuk az autofágia mTOR 
útvonalát, és mértük az infektív virion számot, valamint az apoptosis mértékét. Plakk 
titrálással megállapítottuk, hogy az autofágia-indukció szignifikánsan csökkentette az 
infektív virionszámot. Apoptózis ELISA segítségével megállapítottuk, hogy az 
autofágia-indukció gátolja a rubeolavírus által indukált apoptózist. A rubeolavírus 
tehát két celluláris antivirális mechanizmust képes blokkolni az autofágia gátlása 
révén. 
Mivel az autofágia fontos szerepet játszik az embriogenezis folyamatában, 
feltételezzük, hogy a rubeolavírus autofágiát gátló hatása hozzájárulhat a kongenitális 
rubeola szindróma során kialakuló súlyos magzati ártalomhoz. 
A herpes simplex vírusok autofágiára gyakorolt hatása 
Indirekt immunfluoreszencia segítségével megállapítottuk, hogy a SIRC sejtvonal 
fogékony mind a herpes simplex vírus-1 mind pedig a herpes simplex vírus-2 
fertőzésre. 
Transzmissziós elektronmikroszkópia segítségével tanulmányoztuk a herpes simplex 
vírus-1 fertőzés hatására létrejövő intranukleáris és intracitoplazmatikus replikációs 
kompartmentek, valamint a citoplazmában kialakuló auto- és xenofágiás vakuolumok 
jelenlétét. Ezen vizsgálatok egyértelműen bizonyították a virionok, valamint számos 
auto-, illetve xenofagoszóma jelenlétét a fertőzött sejtekben. 
Az Atg5 és az LC3B intracelluláris lokalizációját indirekt immunfluoreszcenciás 
vizsgálat segítségével tanulmányoztuk bazális autofágia során. Kísérleteink a kontroll 
sejtekben halvány, diffúz citoplazmatikus festődést mutattak ki, ami a bazális 
autofágia alacsony aktivitására utal 24 órás sejtkultúrákban. Ezzel szemben, a vírussal 
fertőzött mintákban intenzív, pöttyözött Atg5 és LC3B festődés volt kimutatható; a 
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számos nagyméretű autofagoszóma jelenlétének köszönhetően. Ezen adatok arra 
utalnak, hogy a herpes simplex vírus-1 befolyásolja az Atg5 és az LC3B 
autofagoszómális marker proteinek intracelluláris lokalizációját.  
Western blot analízissel tanulmányoztuk az LC3B-I és -II proteinek szintjét. A 
fertőzetlen kultúrákban az LC3B mindkét formája kimutatható volt a tenyésztés 15. 
órájában, és az LC3B-II alacsony szintje az autofágia kis mértékű alap aktivitására 
utalt. Az LC3B-II szintje jelentősen növekedett mind herpes simplex vírus-1, mind 
herpes simplex vírus-2 hatására. A fertőzés tehát fokozza az LC3B lipidációját.    
Az autofágiás-fluxus vizsgálatára irodalmi adatoknak megfelelően bafilomycin A1 
kezelést alkalmaztunk. Megállapítottuk, hogy a vírussal fertőzött és bafilomycin A1-
gyel kezelt mintákban a lipidált LC3B szintje kissé alacsonyabb volt, mint a 
bafilomycin A1 kontrollé. A herpes simplex vírus-1 és a herpes simplex vírus-2 tehát 
valamelyest fékezi az autofágiás fluxust.  
A citoplazmatikus acidifikáció mértékét a herpes simplex vírus fertőzés során is 
acridine orange festés segítségével vizsgáltuk. Megállapítottuk, hogy mind a herpes 
simplex vírus-1 mind pedig a herpes simplex vírus-2 fertőzés hatására fokozódik a 
citoplazmatikus acidifikáció mértéke. 
Propidium jodid / annexin V kettős festéssel tanulmányoztuk a herpes simplex vírusok 
sejtkárosító hatását. Megállapítottuk, hogy az apoptotikus mechanizmusok fontos 
szerepet játszanak mind a herpes simplex vírus-1 mind a herpes simplex vírus-2 
citopátiás hatásában.   
Végül tanulmányoztuk az autofágia és az apoptózis közötti kölcsönhatást is. 
Bafilomycin A1-gyel gátoltuk az autofágiát, majd apoptózis ELISA-val mértük a 
sejtek herpes simplex vírus fertőzésre adott apoptotikus válaszát. Eredményeink 
szerint az autofágia gátlása jelentősen fokozta a mind a herpes simplex vírus-1 mind 
pedig a herpes simplex vírus-2 által indukált apoptózis mértékét.  
Eredményeink arra engednek következtetni, hogy mind a herpes simplex vírus-1 mind 
pedig a herpes simplex vírus-2 autofágiát indukál a SIRC corneális sejtvonalon. 
Ezáltal a herpes simplex vírus fertőzések kiváltják az egyik legjelentősebb celluláris 
védekező mechanizmus, az autofágia fokozódását. Ezek az adatok hozzájárulhatnak a 
herpes simplex vírusok által okozott szemészeti és egyéb kórképek patogenezisének 
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